Optimization of chemotherapy in digestive system cancers with special regard to metastatic colorectal cancer;Optimiser la chimiotherapie dans les cancers digestifs. L'exemple des cancers colorecteaux metastases

Hepato-Gastro

Volumn 4, Issue 2 SUPPL., 1997, Pages 91-101

  Rougier, Philippe ^a   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; SPARFOSIC ACID;

BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030892459     PISSN: 12537020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Scheithauer W, Rosen H, Kornek GV. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer Br Med J 1993 ; 306 : 752-5
2. Erlichman C, Fine S, Wong A A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988 ; 6 : 469-75.
3. Poon MA, O'Connell MJ, Moertel CG. Biochemical modulation of fluorouracil : evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989 ; 7 : 1407-18
4. Nordic gastrointestinal tumor adjuvant therapy group. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma : a randomized trial. J Clin Oncol 1989 ; 7 . 1437-46.
5. Nordic gastrointestinal tumor adjuvant therapy group Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer : a randomized trial. J Clin Oncol 1992 ; 10 : 904-11.
6. Rougier P, Laplanche A, Huguier M. Hepatic arterial infusion of fioxuridine in patients with liver metastases from colorectal carcinoma : long-term results of a prospective randomized trial. J Clin Oncol 1992 , 10 . 1112-8.
7. Allen-Mersh TG, Earlam S, Fordy C. Quality of life and survival with continous hepatic-artery floxiuridine infusion for colorectal liver metastases. Lancet 1994 ; 344 1255-60.
8. Köhne-Wompner CH, Schmoll HJ, Harstrick A, et al Chemotherapeutic strategies in metastatic colorectal cancer. an overview of current clinical trials. Semin Oncol 1992 ; 19 105-25
9. Heidelberger C, Chaudari NK, Danneberg P. Fluorinated pyrimidine. A new class of tumor-inhibitory componds. Nature 1957 ; 179 : 663-6.
10. Lokich JJ, Ahlgren JD, Gullo JJ. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorecta! carcinoma : a Mid-Atlantic Oncology Program Study J Clin Oncol 1989 ; 7 : 425-32.
11. Rougier P, Paillot B, Laplanche A. End results or a multicentric randomized trial comparing 5FU in continuous systemic infusion (Cl) to bolus administration (B) in measurable metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 1992 , 111 : 163.
12. Seifert P, Baker LH, Reed ML. Comparison of continous infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975 ; 36 : 123-8.
13. Weinerman B, Shah A, Fields A Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 1992 ; 15 : 518-23
14. Leichman CG, Fleming TR, Muggia FM. Phase II study of fluorouracil and its modulation in advanced colorectal cancer : a Southwest Oncology Group study. J Clin Oncol 1995 ; 13 : 1303-11.
15. Rougier Ph, Ducreux M, Seite JF. Cancers digestifs. Place de la chimiothérapie antitumorale. Arnette Blackwell, Paris, 1996.
16. Petrelli N, Herrera L, Rustum Y A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987 , 5 . 1559-65.
17. Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer : evidence in terms of response rate. J Clin Oncol 1992 ; 10 : 896-903.
18. O'Dwyer PJ, Paul AR, Walczak J Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 1990 ; 8 : 1497-503
19. Kemeny N, Conti JA, Seiter K. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. J Clin Oncol 1992 ; 10 : 747-52.
20. Goldberg RM, O'Connell MJ, Wieand HS. A prospective randomized trial of intensive course 5-FU combined with A) the I-isomer of intravenous leucovorin, B) oral (d,l) leucovorin or C) intravenous (d,l) leucovorin for the treatment of advanced colorectal cancer a North Central Cancer Treatment Group Trial Proc Am Soc Clin Oncol 1996 , 15 207 (abstr 471).
21. De Gramont A, Krulik M Cady J. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer Eur J Cancer Clin Oncol 1988 ; 24 . 1499-503.
22. Gamelin E, Dumesnil Y, Maillart P. High doses escalation 5FU plus leucovorin in colorectal cancer, Eur J Cancer 1991 ; 27 (suppl 2) : 89 (absir)
23. Leichman C, Leichman L, Spears CP. Phase II study of prolonged infusion 5 fluorouracil with weekly leucovorin in disseminated colorectal cancer, Proc Am Soc Clin Concol 1991 , 10 : 143 (absir).
24. Loeffler T, Weber F, Hausamen T Perfusion continue prolongée de 5-fluorouracile associée à l'administration intermittente de hautes doses d'acide folinique dans les cancers recto-coliques évolués et métastatiques . résultats d'une étude pilote. In : Machover D, Rustum Y (eds). Résistance métabolique aux fluoropyrimidines : données actuelles et perspectives. Paris, Léderlé, 1990, pp. 39-43.
25. Tempero M, Berg A, Block M. A phase 11 trial of protracted therapy with 5-fluorouracil and leucovorin in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993 ; 12 . 201.
26. De Gramont A, Bosset JF, Milan C. A prospectively randomized trial comparing 5FU bolus with low dose folinic acid (FUFOLId) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer. Proc Am Soc Clin Oncol 1995 ; 14.
27. Ardalan B, Chua L, Tian E. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991 ; 9 : 625-30.
28. Weh HJ, Wilke HJ, Dierlamm J. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreafed patients witn metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO]. Ann Oncol 1994 ; 5 : 233-7.
29. Diaz-Rubio E, Aranda E, Camps C. A phase II study of weekly 48-hour infusions with high-dose fluorouracil in advanced colorectal cancer : an alternative to biochemical modulation. A trial of the Spanish Cooperative Group for Tumor Therapy (T.T.) Gastro-intestinal. J Infus Chemother 1994 ; 4 : 58-62.
30. Brochure sur le 5FU. Produits Roche, Neuilly, janvier 1994.
31. Hryniuk WM. The importance of dose-intensity in the outcome of chemotherapy. In : De Vita VT, Helmann, S, Rosenberg, SA (eds) : Important advances in oncology. Philadelphia, Uppincott, JB, 1988 ; 121-5.
32. Milano G, Etienne MC, Renee N. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994 ; 12 : 1291-5
33. Gamelin EC, Danquechin-Dorvai EM, Dumesnil. Relationship between 5-fluorouracil dose-intensity and therapeutic response in patients with advanced colorectal cancer receiving 5-FU containing infusional therapy. Cancer 1996 ; 77 : 441-51.
34. Levi F, Misset JL, Brienza S. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel program-mable pump. Cancer 1992 ; 69 : 893-900.
35. Bajetta E, Di Bartolomeo M, Somma L Doxifluridine in patients with 5-FU resistant colorectal cancer Eur J Cancer 1995 , 31A (suppl 5). S147 (abstr).
36. Gonzalez-Baron M, Feliu J, de la Gandara I Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995 ; 31A : 2215-9.
37. Horikoshi N, Mitachi Y, Sakata Y. S-1, new oral fluoropyrimidine is very active in patients with advanced gastric cancer (early phase II study). Proc Am Soc Clin Oncol 1996 ; 15 : 206 (abstr 466).
38. Cunningham D, Zalcberg J, Smith I. « Tomudex » (ZD1694) : a novel thymidylafe synthetase inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 1996 ; 7 179-82
39. Seitz JF, Cunningham D, Rath U, Final results and survival data of a large randomised trial of « tomudex » in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5FU + LV). Proc Am Soc Clin Oncol 1996; 15: 201 (abstr 446)
40. Diaz-Rubio E, Zaniboni A, Gastiaburu J Phase II multicentric trial of oxaliplatin (L-OHP) as first line chemotherapy in metastatic colorectal carcinoma (MCRC). Proc Am Soc Clin Oncol 1996 ; 15 : 207.
41. Levi F, Perpoint B, Garufi C Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at arcadian rhythm modulated rate. Eur J Cancer 1993 . 29A (suppl 6) ; 598
42. Louvet C, Bleiberg H, Gamelin E. Oxaliplatin (L-OHP) synergistic clinical activity with 5-fluorouracil (FU) in FU resistant colorectal cancer (CRC) patients (PTS) is independent of FU ± Folinic acid (FA) schedule, Proc Am Soc Clin Oncol 1996 ; 15 : 206.
43. Rougier P, Culine S, Bugat R. Multicentric phose II study of first-line CPT-11 (irinotecan) in advanced colorectal cancer (CRC). Preliminary results. Proc Am Soc Clin Oncol 1994 , 13 : 200.
44. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in non treated patients with metastatic colorectal cancer. J Clin Oncol 1996 ; 14 : 709-15.
45. Rothenberg ML, Eckardt JR, Kuhn JG. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1990 ; 14 : 1128-35.
46. Bugat R, Rougier P, Douillard JY. Efficacy of irinotecan HCI (CPT11) in patients with metastatic colorectal cancer after progression while receiving a 5FU based chemotherapy. Proc Am Soc Clin Oncol 1995 ; 14 : 222.
47. Scheithauer W, Depisch D, Komek G. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer 1994 ; 73 1562-8.
48. Marsh JC, Bertino JR, Katz KH. The influence of drug interval on the effect of methotrexate ana fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 1991 ; 9 : 371-80.
49. Blijham GH, Stellestags J, Sahmoud T. The modulation of high-dose 5-fluorouracil (HD-FD) with low-dose methofrexate [LD-MTX) in metastatic colorectal cancer : a phase III study of the EORTC Gl Cancer Cooperative Group. Proc Am Soc Clin Oncol 1993 , 12:199
50. Advanced colorectal cancer meta-analysis project. Meta-analysts of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994 ; 12 : 960-9.
51. Wadler S, Wiemik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 1990 , 17: 16-21 ; discussion 38-41.
52. Kocha W. 5-fluorouracil (5-FU) plus interferon alfa-2a (Roferon-A) versus 5-fluorouracil plus leucovorin (LV) in metastatic colorectal cancer. Results of a multicentre, multinational phase III study. Proc Am Soc Clin Oncol 1993 , 12 . 193.
53. Peters GJ, van der Wilt CL, van Triest B. Thymidylate synthase and drug resistance, Eur J Cancer 1995 , 31A . 1299-305.
54. Leichman L, Lenz HJ, Leichman CG. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers : preliminary report from an ongoing trial. Eur J Cancer 1995; 31 A: 1306-10.
55. Lenz HJ, Danenberg KD, Leichman CG. P53 status and thyrnidylate synthetase levels are predictors of chemotherapy efficocy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1996 ; 15 : 216.
56. Bajoj R, Agarwal V, Neuberg D. Prognostic implications of C-Kl-RAS2 (RAS) mutations in patients with advanced colorectal cancer treated with 5-fluorouracil [5-FU) and interferon (IFN) : an Eastern Cooperative Oncology Group (ECOG) study. Proc Am Soc Clin Oncol 1996 ; 15 - 210.